Cargando…

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation

BACKGROUND: Diltiazem, a moderate cytochrome P450 3A4 isozyme/P‐glycoprotein inhibitor, may potentiate the bleeding risk of direct oral anticoagulants (DOACs) through pharmacokinetic interactions. We evaluated the association between concomitant use of diltiazem with DOACs and bleeding among patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yunwen, Chang, Alex R., Inker, Lesley A., McAdams‐DeMarco, Mara, Grams, Morgan E., Shin, Jung‐Im
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707838/ https://www.ncbi.nlm.nih.gov/pubmed/35861836 http://dx.doi.org/10.1161/JAHA.122.025723

Ejemplares similares

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care
por: Bosi, Alessandro, et al.
Publicado: (2021)

Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis
por: Tan, Jingwen, et al.
Publicado: (2016)

Concomitant diabetes with atrial fibrillation and anticoagulation management considerations
por: Kreutz, Reinhold, et al.
Publicado: (2020)

Diltiazem Dosing Strategies in the Management of Atrial Fibrillation With Rapid Ventricular Rate
por: Bishop, James, et al.
Publicado: (2021)

Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk
por: Cid, Allison, et al.
Publicado: (2022)

The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2020)

Cardiac Arrest Following Treatment With Diltiazem for Atrial Fibrillation With Rapid Ventricular Response
por: Lee, Woo Kyung, et al.
Publicado: (2020)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation
por: Raccah, Bruria Hirsh, et al.
Publicado: (2021)

Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort
por: Said, Ahmad, et al.
Publicado: (2020)

Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults
por: Hill, Kevin, et al.
Publicado: (2021)

Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
por: Atterman, Adriano, et al.
Publicado: (2021)

Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding
por: Scridon, Alina, et al.
Publicado: (2023)

Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation
por: Giustozzi, Michela, et al.
Publicado: (2020)

Rate control with intravenous diltiazem, verapamil, and metoprolol in acute atrial fibrillation with rapid ventricular rate
por: Medeiros, Tia, et al.
Publicado: (2021)

Comparison of diltiazem and metoprolol for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis
por: Sharda, Saurabh C., et al.
Publicado: (2022)

Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study
por: Diemberger, Igor, et al.
Publicado: (2022)

New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation
por: Raposeiras Roubín, Sergio, et al.
Publicado: (2020)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
por: Zappulla, Paolo, et al.
Publicado: (2021)

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Diltiazem Prophylaxis for the Prevention of Atrial Fibrillation in Patients Undergoing Thoracoabdominal Esophagectomy: A Retrospective Cohort Study
por: Hochreiter, Marcel, et al.
Publicado: (2020)

Personalized rate control treatment for atrial fibrillation: a prospective case-control study on the use of diltiazem
por: Spadotto, A, et al.
Publicado: (2023)

Weight changes following antidiabetic mediation use: Real‐world evidence from health system data
por: Lyu, Beini, et al.
Publicado: (2022)

Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
por: Lyu, Beini, et al.
Publicado: (2022)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

First Reported Case of Rhabdomyolysis Associated with Concomitant Use of Cyclosporin, Diltiazem, and Simvastatin
por: Fuah, Kar Wah, et al.
Publicado: (2021)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
por: Ballestri, Stefano, et al.
Publicado: (2022)

Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation
por: Wintgens, L. I. S., et al.
Publicado: (2019)

Diltiazem efficacy and CYP2D6 gene polymorphism in patients with atrial fibrillation with rapid ventricular response
por: Uluturk, Mehmet, et al.
Publicado: (2023)

Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics
por: Yagi, Tatsuya, et al.
Publicado: (2022)

Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
por: Prídavková, Dana, et al.
Publicado: (2019)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Revised HAS‐BLED score for bleeding prediction in atrial fibrillation patients with oral anticoagulants
por: Methavigul, Komsing
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h14ko8fahtmb78sviga3euugah